Artis supports autologous and allogeneic CAR-T programs through a modular cGMP platform designed for scalable manufacturing, integrated analytics, and efficient GMP transfer.
Our Platform Optimized for Scale-up and Transfer (POSTmark) process aligns development and cGMP manufacturing through mirrored equipment, scale-down models, and standardized workflows, enabling faster, lower-risk transfer for CAR-T programs.
Fresh and frozen chain-of-custody workflows supporting diverse manufacturing strategies
Flexible manufacturing spaces supporting diverse CAR-T process strategies
In-house QC testing, release analytics, and GMP fill/finish capabilities
Located near leading clinical centers and research hospitals to support clinical manufacturing coordination
Mirrored development systems and scale-down models supporting efficient GMP transfer
Coordinated viral vector and CAR-T manufacturing workflows designed to move programs into GMP with fewer scheduling and quality bottlenecks
GMP-ready synthetic DNA as a plasmid alternative for lentiviral vector production, available in as little as 2 weeks
POSTmark supports an end-to-end autologous CAR-T workflow aligned from development through cGMP manufacturing
Patient cell subset selection using Rotea & CliniMACS Plus systems
CAR lentiviral vectors introduced under mirrored development & GMP conditions
Autologous expansion in G-Rex systems & allogeneic expansion in Xuri platforms
GMP-compliant formulation & filling into bags or vials
In-house identity, potency, purity, & persistence testing
Artist BioSolutions’ CAR-T workflow reduces time and costs risks through an end-to-end process. For autologous CAR-T, our workflow is just 7 days from receipt to QC with both cell therapy and lentiviral manufacturing in a single facility.
T cell
Non-T
Viability
Flow cytometry
Flow cytometry
Automated cell counters/ Flow cytometry
Frequency (%)
Frequency (%)
Cells/mL
In-vitro
Cytotoxicity
Cytokine production
Flow cytometry
Flow cytometry/ELISA
% Cytotoxicity
% positive / Concentration
Vector copy number
replication competence
Compendial (myco, sterility, endotoxin)
qPCR/ddPCR
qPCR
Assay specific
Copy/Cell
VSVG (Copies/mL)
Detection (Pass/Fail)
Within the POSTmark framework, development and GMP manufacturing are aligned through standardized workflows, supporting efficient technology transfer and scalable production.
cGMP facilities and operations are designed to meet applicable US FDA regulations (including 21 CFR Parts 11, 210, 211, 610, and 1271) and relevant ICH quality guidelines.
Last November we published POSTmark CAR-T: Delivering Therapies Without Delay, arguing that manufacturing continuity—not biology—is the rate-limiting step for most CAR-T programs. This year at ASGCT, just months later, it was abundantly clear that the conversation has shifted under everyone’s feet.
Stem Cells 
CAR-T 
AAV Delivery 
LVV Delivery 
Other Viral Vectors 
Extracellular Vesicles 
Nanoparticles